Literature DB >> 16387794

Bioenergetic and functional consequences of stem cell-based VEGF delivery in pressure-overloaded swine hearts.

Xiaohong Wang1, Qingsong Hu, Abdul Mansoor, Joseph Lee, Zongli Wang, TeChung Lee, Arthur H L From, Jianyi Zhang.   

Abstract

In an established swine model of severe left ventricular (LV) hypertrophy (LVH), the bioenergetic and functional consequences of transplanting autologous mesenchymal stem cells (MSCs) overexpressing vascular endothelial growth factor (VEGF-MSCs) into the LV were evaluated; transplantation was accomplished by infusion of VEGF-MSCs into the interventricular cardiac vein. Specifically, the hypertrophic response to aortic banding was compared in seven pigs treated with 30 million VEGF-MSCs, eight pigs treated with 30 million MSCs without VEGF modification, and 19 untreated LVH pigs. Eight pigs without banding or cell transplantation (normal) were also studied. Four weeks postbanding, LV wall thickening (MRI), myocardial blood flow (MBF), high-energy phosphate levels ((31)P magnetic resonance spectroscopy), and hemodynamic measurements were obtained under basal conditions and during a catecholamine-induced high cardiac workstate (HCW). Although 9 of 19 untreated banded pigs developed clinical evidence of biventricular failure, no MSCs-treated animal developed heart failure. MSCs engraftment was present in both cell transplant groups, and both baseline and HCW MBF values were significantly increased in hearts receiving VEGF-MSCs compared with other groups (P < 0.05). During HCW, cardiac inotropic reserve (defined as the percent increase of rate pressure product at HCW relative to baseline) was normal in the VEGF-MSCs group and significantly decreased in all other banded groups. Additionally, during HCW, the myocardial energetic state [reflected by the phosphocreatine-to-ATP ratio (PCr/ATP)] of VEGF-MSCs-treated hearts remained stable, whereas in all other groups, PCr/ATP decreased significantly from baseline values (P < 0.05, each group). Myocardial von Willebrand factor and VEGF mRNA expressions and myocardial capillary density were significantly increased in VEGF-MSCs-treated hearts (P < 0.05). Hence, in the pressure-overloaded LV, transplantation of VEGF-MSCs prevents LV decompensation, induces neovascularization, attenuates hypertrophy, and improves MBF, myocardial bioenergetic characteristics, and contractile performance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16387794     DOI: 10.1152/ajpheart.00871.2005

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  29 in total

Review 1.  Genetic engineering of mesenchymal stem cells and its application in human disease therapy.

Authors:  Conrad P Hodgkinson; José A Gomez; Maria Mirotsou; Victor J Dzau
Journal:  Hum Gene Ther       Date:  2010-10-22       Impact factor: 5.695

Review 2.  The Role of the Microenvironment in Controlling the Fate of Bioprinted Stem Cells.

Authors:  Lauren N West-Livingston; Jihoon Park; Sang Jin Lee; Anthony Atala; James J Yoo
Journal:  Chem Rev       Date:  2020-06-19       Impact factor: 60.622

3.  Assessment of a nuclear affinity labeling method for tracking implanted mesenchymal stem cells.

Authors:  Merced Leiker; Gen Suzuki; Vijay S Iyer; John M Canty; Techung Lee
Journal:  Cell Transplant       Date:  2008       Impact factor: 4.064

4.  A fibrin patch-based enhanced delivery of human embryonic stem cell-derived vascular cell transplantation in a porcine model of postinfarction left ventricular remodeling.

Authors:  Qiang Xiong; Katherine L Hill; Qinglu Li; Piradeep Suntharalingam; Abdul Mansoor; Xiaohong Wang; Mohammad Nurulqadr Jameel; Pengyuan Zhang; Cory Swingen; Dan S Kaufman; Jianyi Zhang
Journal:  Stem Cells       Date:  2011-02       Impact factor: 6.277

5.  Assessment of the green florescence protein labeling method for tracking implanted mesenchymal stem cells.

Authors:  Yinghua Guo; Longxiang Su; Junlou Wu; Dong Zhang; Xiaojun Zhang; Guizhi Zhang; Tianzhi Li; Junfeng Wang; Changting Liu
Journal:  Cytotechnology       Date:  2012-02-29       Impact factor: 2.058

6.  Vascular endothelial growth factor (VEGF) as a key therapeutic trophic factor in bone marrow mesenchymal stem cell-mediated cardiac repair.

Authors:  David Zisa; Arsalan Shabbir; Gen Suzuki; Techung Lee
Journal:  Biochem Biophys Res Commun       Date:  2009-10-15       Impact factor: 3.575

Review 7.  Growth factor regulation of proliferation and survival of multipotential stromal cells.

Authors:  Melanie Rodrigues; Linda G Griffith; Alan Wells
Journal:  Stem Cell Res Ther       Date:  2010-10-26       Impact factor: 6.832

8.  Permanent coronary artery occlusion: cardiovascular MR imaging is platform for percutaneous transendocardial delivery and assessment of gene therapy in canine model.

Authors:  Maythem Saeed; Alastair Martin; Alexis Jacquier; Matthew Bucknor; David Saloner; Loi Do; Philip Ursell; Hua Su; Yuet W Kan; Charles B Higgins
Journal:  Radiology       Date:  2008-09-09       Impact factor: 11.105

Review 9.  Cardiac MR imaging: current status and future direction.

Authors:  Maythem Saeed; Tu Anh Van; Roland Krug; Steven W Hetts; Mark W Wilson
Journal:  Cardiovasc Diagn Ther       Date:  2015-08

10.  MR assessment of myocardial perfusion, viability, and function after intramyocardial transfer of VM202, a new plasmid human hepatocyte growth factor in ischemic swine myocardium.

Authors:  Maythem Saeed; Alastair Martin; Phillip Ursell; Loi Do; Matt Bucknor; Charles B Higgins; David Saloner
Journal:  Radiology       Date:  2008-08-05       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.